Vericel (NASDAQ:VCEL) Stock Price Expected to Rise, HC Wainwright Analyst Says

Key Points

• HC Wainwright raised its price target on Vericel from $72 to $75 and reiterated a Buy rating, implying 44.84% upside from the stock’s current price.
• Vericel beat third-quarter earnings and revenue estimates: EPS was $0.27 versus $0.06 expected, and revenue rose 26.5% year over year to $85.37 million. The company also raised its 2026 revenue guidance to $344–$346 million.
• Analyst views are broadly positive, with four Buy ratings and two Holds, though the consensus price target of $58.20 is below HC Wainwright’s target. A separate analysis also flagged possible valuation concerns.

Vericel (NASDAQ:VCEL - Get Free Report) had its price target increased by stock analysts at HC Wainwright from $72.00 to $75.00 in a note issued to investors on Friday, Benzinga reports. The firm presently has a "buy" rating on the biotechnology company's stock. HC Wainwright's price target points to a potential upside of 44.84% from the stock's current price.

VCEL has been the topic of several other research reports. Weiss Ratings reiterated a "hold (c)" rating on shares of Vericel in a research note on Thursday, October 29th. Truist Financial cut their price objective on Vericel from $58.00 to $52.00 and set a "buy" rating for the company in a research report on Wednesday, October 14th. Wall Street Zen upgraded Vericel from a "hold" rating to a "buy" rating in a research report on Saturday, July 18th. Canaccord Genuity Group set a $60.00 target price on Vericel in a report on Thursday, July 30th. Finally, TD Cowen boosted their target price on Vericel from $55.00 to $58.00 and gave the stock a "buy" rating in a research report on Friday, July 31st. Four equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $58.20.

Vericel Stock Performance

VCEL stock opened at $51.78 on Friday. Vericel has a one year low of $28.95 and a one year high of $55.60. The company's fifty day moving average price is $40.74 and its 200-day moving average price is $38.80. The company has a market capitalization of $2.65 billion, a PE ratio of 110.17 and a beta of 1.08.

Vericel (NASDAQ:VCEL - Get Free Report) last issued its earnings results on Thursday, November 5th. The biotechnology company reported $0.27 earnings per share for the quarter, topping analysts' consensus estimates of $0.06 by $0.21. The firm had revenue of $85.37 million during the quarter, compared to analyst estimates of $77.95 million. Vericel had a net margin of 7.91% and a return on equity of 6.91%. Vericel's revenue for the quarter was up 26.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.10 earnings per share. On average, research analysts predict that Vericel will post 0.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Vericel

Large investors have recently bought and sold shares of the business. MCF Advisors LLC raised its holdings in Vericel by 293.0% during the 2nd quarter. MCF Advisors LLC now owns 782 shares of the biotechnology company's stock valued at $35,000 after buying an additional 583 shares during the period. Ameritas Advisory Services LLC bought a new stake in Vericel in the second quarter worth $36,000. Allworth Financial LP purchased a new position in Vericel during the second quarter worth $60,000. Integrated Wealth Concepts LLC purchased a new position in Vericel during the second quarter worth $72,000. Finally, GAMMA Investing LLC increased its position in Vericel by 17.7% during the second quarter. GAMMA Investing LLC now owns 1,886 shares of the biotechnology company's stock valued at $84,000 after acquiring an additional 283 shares during the last quarter.

Key Stories Impacting Vericel

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Third-quarter revenue rose 26% year over year to $85.4 million, while net income increased 179% to $14.2 million. EPS of $0.27 also beat analyst expectations, as did revenue of $85.4 million versus estimates of about $78 million. Vericel third-quarter results and guidance
• Positive Sentiment: Vericel raised its 2026 revenue guidance to $344 million–$346 million, above the roughly $336 million consensus estimate, and forecast a 28% adjusted EBITDA margin. The higher outlook signals continued business momentum. Vericel raises FY2026 outlook
• Positive Sentiment: Coverage highlighted record sales of MACI, Vericel’s cartilage repair product, as a key driver of results and the raised outlook. Vericel record revenue and raised outlook
• Negative Sentiment: A separate analysis characterized VCEL as potentially overvalued relative to its earnings support. That valuation concern could temper investor enthusiasm after the strong results, although the provided article details do not quantify its valuation case. Vericel valuation analysis

Vericel Company Profile

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient's own cells or biologic materials to support tissue repair and healing.

Vericel's primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.